 |
|
|
| |
Safety And Efficacy At 1 Year After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide In Chronic HBV Patients With Risk Factors For TDF Use
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Ed Gane1, Wai-Kay Seto2, Harry L.A. Janssen3, Florin Alexandru Caruntu4, Hyung Joon Kim5, Dzhamal Abdurakhmanov6, Shuhei Nishiguchi7, Andrzej Horban8, Ho Bae9, Shuyuan Mo10, Vithika Suri10, Anuj Gaggar10, John F. Flaherty10, Jia-Horng Kao11, Maurizia Brunetto12, Maria Buti Ferret13
1Auckland Clinical Studies, Auckland, New Zealand; 2Queen Mary Hospital, Hong Kong; 3Toronto General Hospital, Toronto, Canada; 4Institutul National de Boli Infectioase "Prof. Dr. Matei Bals", Bucharest, Romania; 5Chung-Ang Hospital, Seoul, Korea; 6Sechenov University, Clinical Hospital 1, Moscow, Russia; 7Hyogo College of Medicine, Nishinomiya, Japan; 8Warsaw Medical University and Hospital of Infectious Diseases, Warsaw, Poland; 9St.Vincent Medical Center, Los Angeles, CA, USA; 10Gilead Sciences, Inc., Foster City, CA, USA; 11National Taiwan University, Taipei, Taiwan; 12University Hospital of Pisa, Italy; 13Hospital General Universitari Vall d'Hebron and Ciberehd, Barcelona, Spain
|
| |
|
|
|
|
|
